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Rationale: Bronchiolitis obliterans syndrome (BOS), defined by loss
of lung function, develops in the majority of lung transplant recipi-
ents. However, there is a paucity of information on the subsequent
course of lung function in these patients.
Objectives: To characterize the course of FEV1 over time after devel-
opment of BOS and to determine the predictors that influence the
rate of functional decline of FEV1.
Methods: FEV1% predicted (FEV1%pred) trajectories were studied
in 111 lung transplant recipients with BOS by multivariate, linear,
mixed-effects statistical models.
Measurements and Main Results: FEV1%pred varied over time after
BOS onset, with the steepest decline typically seen in the first 6
months (12% decline; p  0.0001). Bilateral lung transplant recipi-
ents had significantly higher FEV1%pred at BOS diagnosis (71 vs.
47%; p  0.0001) and at 24 months after BOS onset (58 vs. 41%;
p  0.0001). Female gender and pretransplant diagnosis of idio-
pathic pulmonary fibrosis were associated with a steeper decline
in FEV1%pred in the first 6 months after BOS diagnosis (p  0.02
and 0.04, respectively). A fall in FEV1 greater than 20% in the
6 months preceding BOS (termed “rapid onset”) was associated
with shorter time to BOS onset (p  0.01), lower FEV1%pred at
BOS onset (p  0.0001), steeper decline in the first 6 months (p 
0.03), and lower FEV1%pred at 2 years after onset (p  0.0002).
Conclusions: Rapid onset of BOS, female gender, pretransplant diag-
nosis of idiopathic pulmonary fibrosis, and single-lung transplanta-
tion are associated with worse pulmonary function after BOS onset.
Keywords: bronchiolitis obliterans syndrome; FEV1; pulmonary
function; prognosis
Lung transplantation is the only viable option for many patients
with chronic, end-stage lung diseases. However, 60% of patients
within 5 years of transplant develop bronchiolitis obliterans syn-
drome (BOS) (1–4), a disease syndrome defined as a fall in FEV1
of greater than 20% from baseline determined by the average
of two measurements made at least 3 weeks apart (5). Median
survival after onset of BOS is 3 to 4 years, with a range of 0 to
9.4 years (6–8). These survival numbers are comparable to other
chronic lung diseases, such as idiopathic pulmonary fibrosis
(IPF). Similarly, although development of BOS is associated
with progressive worsening of lung function, the rate of decline
in FEV1 after onset of BOS is believed to be variable among
patients and over time (9). Although significant effort has been
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The effect of various clinical variables on the course of
FEV1 after bronchiolitis obliterans syndrome onset in lung
transplant recipients remains to be completely determined.
What This Study Adds to the Field
Rapid onset of BOS, female gender, pretransplant diagno-
sis of idiopathic pulmonary fibrosis, and single-lung trans-
plantation are associated with worse pulmonary function
after BOS onset.
made to understand factors associated with the risk of develop-
ment of BOS, little information has been published regarding
the course of FEV1 after onset of BOS and the effect of various
variables on it. This information is important for patient counsel-
ing and management, but is also crucial for designing diagnostic
and therapeutic clinical trials in the field of BOS.
The objectives of this study were to characterize the course
of FEV1 over time after development of BOS, to describe the
natural history of spirometric dysfunction, and to determine the
predictors that influence the rate of functional decline of FEV1
in a large cohort of well-characterized lung transplant recipients.
METHODS
A total of 317 lung transplants were performed in the University of
Michigan Health System between November 1990 and December 2004.
All lung transplant recipients alive 3 months after transplantation with
available post-transplant pulmonary measures were screened for pres-
ence of BOS according to the published guidelines (5) and as described
previously (4). A total of 111 lung transplant recipients who developed
BOS (BOS stages 1 or higher) comprised the study group.
The study was approved by the University of Michigan Institutional
ReviewBoard. All patients were followed by a standardized protocol, as
previously described (4, 10). Pulmonary function testing was performed
following standards established by the American Thoracic Society at
each clinic visit (11). To study the course of FEV1 after onset of BOS,
all follow-up pulmonary function tests were analyzed. Follow-up was
complete until time of death or July 1, 2005. The dataset included
10,317 spirometric observations, with a mean number of 93 ( 102)
observations per patient. Median follow-up time was 5.5 years (95%
confidence interval, 4.3–7.1 yr), with a range of 0.1 to 11.1 years after
onset of BOS.
The predictors analyzed for a potential influence on FEV1 trajectory
after BOS onset included recipient age and gender, transplant date, type
of transplantation (single- [SLT] vs. bilateral lung transplant [BLT]), indi-
cation for transplantation (chronic obstructive pulmonary disease [COPD]
vs. IPF), rate of decline of FEV1 before BOS onset (rapid vs. gradual),
time of BOS onset (early vs. late), and presence of histologic findings of
acute rejection and lymphocytic bronchitis in the post-transplantation
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period before BOS onset. These factors were chosen on the basis of
previous literature, hypothesized associations, and their potential impor-
tance in guiding pretransplant decisions, as elaborated in Discussion. In
addition, each variable that was analyzed contained only information that
was available at the timeofBOSonset.Hence, the resultswill be practically
useful to the clinician at the time a patient is diagnosed with BOS.
Time of BOS onset was defined as “early” if the onset of BOS
occurred within 2 years of transplantation; otherwise it is termed “late”
(8). The BOS onset date was defined as the date of the first of the two
FEV1 measurements used to establish the BOS diagnosis. FEV1 values
at the BOS onset date and those collected approximately 6 months
earlier were used to calculate percent change in the 6 months before
BOS onset. Patients with 20% or greater change in the 6 months before
BOS onset were defined as having a rapid course of BOS onset; the
remaining patients were defined as experiencing a gradual onset. Histo-
logic findings of acute rejection and lymphocytic bronchitis were classi-
fied according to the International Society of Heart and Lung Trans-
plant grading scheme (12). Two categories of pretransplant diagnosis
were evaluated: patients with underlying restrictive physiology and
diagnosis of IPF, and patients with underlying chronic obstructive pul-
monary disease (COPD). The small number of patients in other catego-
ries limited our ability to meaningfully evaluate the impact of those
diagnoses.
Statistical Analysis
Multivariate, linear, mixed-effects statistical models (PROC MIXED,
SAS version 9.1.3; SAS Institute, Cary, NC) were used to estimate
FEV1%pred trajectories for each group of patients, adjusted for con-
founding factors (13). This method was used to estimate the mean
FEV1%pred during the time from 0 to 24 months post-BOS, while
allowing for correlation between measurements on a particular BOS
patient. In addition, the method adjusts for the relative absence of
spirometric values for those patients who die early or otherwise leave
the study. This particular analysis incorporated linear spline terms to
allow trajectories to change every 6 months from the time of develop-
ment of BOS. Cited percent increases or decreases in FEV %pred
are reported as relative changes rather than absolute changes, unless
otherwise noted. In addition, average times to BOS were compared
across groups using the two-sample t test.
RESULTS
Characteristics of the Study Cohort
The 111 lung transplant recipients with BOS included 49 males
and 62 females, with a mean age at the time of transplantation
of 52 years (range, 19–64 yr). The cohort included 91 SLT and
20 BLT patients. Primary indications for transplantation in the
SLT cohort included emphysema (n  76), IPF (n  12), and
primary pulmonary hypertension (n  3). Indications for BLT
included emphysema (n  14), IPF (n  2), primary pulmonary
hypertension (n  1), and cystic fibrosis (n  3).
Average Course of FEV1 over Time after BOS Onset
The course of FEV1%pred was evaluated for changes in trajecto-
ries at 6, 12, and 18 months after BOS onset. Figure 1 demon-
strates the FEV1%pred for the average patient profile adjusted
for age, gender, pretransplant diagnosis, time-to-BOS, type of
transplant, transplant date, and 6-month pre-BOS relative
change in FEV1 (rapid vs. gradual onset of BOS). The rate of
decline of FEV1%pred (trajectory) changed significantly during
the first 2 years after BOS onset (p  0.0001). The steepest
decline in FEV1%pred was seen in the first 6 months and was
highly statistically significant (12% decline; p  0.0001). This
was followed by continuing significant decline between 6 and
12 months (4% decline; p  0.01), a decrease in the rate of
decline of FEV1%pred between 12 and 18 months (3% decline;
p 0.17), and stabilization of FEV1%pred from 18 to 24 months
(3% increase; p  0.23) (Figure 1).
Figure 1. Courseof FEV1%predicted(FEV1%pred)after bronchiolitis obliter-
ans syndrome (BOS) onset in lung transplant recipients. FEV1%pred for
the average patient profile adjusted for age, pretransplant diagnosis,
time-to-BOS, type of transplant, transplant date, and 6-month pre-BOS
relative change in FEV1 (rapid vs. gradual onset of BOS) is shown. Num-
bers of patients at the onset of each time interval are displayed at the
bottom. The rate of decline of FEV1%pred changed significantly during
the first 2 years after BOS onset (p  0.0001). The steepest decline was
seen in the first 6 months (12% decline; p  0.0001). The decline
between 6 and 12 months was also significant (4% decline; p  0.01).
Effect of Gender on the Course of FEV1 after BOS Onset
Time from transplant to BOS onset was similar in males (889 d)
versus females (891 d; p  0.99), and no significant difference
was observed in FEV1%pred at BOS onset (p 0.62). However,
subsequent trajectories for FEV1%pred differed by gender after
adjusting for age, pretransplant diagnosis, time-to-BOS, type of
transplant, transplant date, and 6-month pre-BOS relative
change in FEV1 (rapid vs. gradual onset of BOS) (Figure 2). In
particular, the 0–6 months declining trajectory for FEV1%pred
was significantly less steep for male versus female patients
(8 vs. 15% decrease for males vs. females, p  0.02). Gender-
specific trajectories between 6 and 24 months were similar (p 
0.76), and differences in FEV1%pred at 24 months did not
reach statistical significance (p  0.13), although, at this time,
FEV1%pred was 11% higher in males than in females.
Effect of Pretransplant Diagnosis on the Course of FEV1 after
BOS Onset
Average time from transplantation to development of BOS was
910 days in the patients with COPD (n  90) and 737 days in
the IPF cohort (n  14) (p  0.35). No statistically significant
difference was noted in the FEV1%pred at BOS onset in the
two groups (p  0.09) (Figure 3). However, a steeper decline
of FEV1%pred was seen during the first 6 months after BOS
onset for recipients with IPF compared with recipients with
COPD, which was statistically significant when adjusted for age,
gender, time-to-BOS, type of transplant, and 6-month pre-BOS
relative change in FEV1 (p  0.04). Observed differences in the
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Figure 2. Gender-specific course of FEV1%pred after BOS onset in lung
transplant recipients. Trajectories for FEV1%pred after BOS onset for
male and female patients are shown, adjusted for age, pretransplant
diagnosis, time-to-BOS, type of transplant, transplant date, and
6-month pre-BOS relative change in FEV1 (rapid vs. gradual onset of
BOS). The declining trajectory between 0 and 6months was significantly
less steep for male versus female patients (p  0.02). This difference
remained significant after adjusting for the FEV1 value at BOS onset
(p  0.046). Numbers of male and female patients at the onset of each
time interval are displayed at the bottom.
shape of the FEV1%pred trajectories after the first 6 months
were not statistically significant (p  0.41).
Effect of Type of Transplant on the Course of FEV1 after Onset
of BOS
There was a nonsignificant trend toward longer time to develop-
ment of BOS in BLT recipients (n  20) compared with SLT
recipients (n  91) (1,178 vs. 827 d; p  0.16). Significantly
higher FEV1%pred was seen at BOS onset in BLT compared
with SLT recipients (71 vs. 47%; p  0.0001). Figure 4 shows
the course of FEV1%pred after BOS onset for SLT versus BLT
patients, adjusted for gender, age, diagnosis, time-to-BOS, trans-
plant date, and 6-month pre-BOS relative change in FEV1. A
significantly steeper slope seen in BLT recipients during the first
6 months (p  0.004) vanished when adjusted for differences in
FEV1%pred at BOS onset (p 0.17), suggesting that this steeper
decline in BLT patients is due more to their typically higher
initial FEV1%pred value at BOS onset than to the type of trans-
plant procedure. This is known as a “floor effect” in statistical
parlance, because those with lower FEV1%pred values at onset
have less opportunity to decline further. No significant difference
was seen in the rate of decline of FEV1%pred after 6 months
(p  0.23). At 24 months after BOS onset, BLT recipients main-
tained a 42% higher FEV1%pred compared with SLT recipients
(p 0.0001).A studyof the interaction between transplant type and
pretransplant diagnosis echoed the aforementioned observations in
the COPD population (data not shown). Small sample size limited
Figure 3. Course of FEV1%pred after BOS onset in lung transplant recipi-
ents by pretransplant diagnosis. Trajectories for FEV1%pred after BOS
onset for patients with pretransplant diagnosis of idiopathic pulmonary
fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are
shown, adjusted for age, gender, time-to-BOS, type of transplant, trans-
plant date, and 6-month pre-BOS relative change in FEV1 (rapid vs.
gradual onset of BOS). The steeper decline during the 6 months after
BOS onset for recipients with IPF compared with those with COPD was
statistically significantwhen adjusted for age, gender, time-to-BOS, type
of transplant, transplant date, and 6-month pre-BOS relative change
in FEV1 (p  0.04). Numbers of patients with COPD and IPF at the
onset of each time interval are displayed at the bottom.
the ability to verify the direction and magnitude of changes due
to transplant type in the remaining diagnoses.
Effect of Pre-BOS FEV1 Change and Time to BOS Onset on the
Subsequent Course of FEV1
A total of 42 of 111 patients (38%) had FEV1 values decreasing
20% or more during the 6 months before BOS onset (rapid
onset); the remaining 69 patients were considered gradual onset
patients. Patients with rapid onset had a significantly shorter time
from transplant to BOS (643 d) compared with those with gradual
onset (1,010 d; p  0.01), and had an 18% lower FEV1%pred
at onset compared with gradual-onset patients (p  0.0001)
(Figure 5). Furthermore, these patients continued to exhibit a
steeper decline in FEV1%pred during the first 6 months of BOS,
adjusting for gender, age, type of transplant, transplant date,
pretransplant diagnosis, time-to-BOS, and level of FEV1%pred
at BOS onset (p  0.03). FEV1%pred at 24 months after BOS
onset was 33% higher in the patients with gradual versus rapid
onset (p  0.0002).
Patients were also compared on the basis of time to BOS
onset. A total of 62 patients (56%) developed BOS within
2 years of transplant (early onset). Patients with early onset were
observed to have lower FEV1%pred values over time (Figure 6A),
although this trend did not reach statistical significance (differ-
ence in FEV1%pred at BOS onset, p  0.22; difference in decline
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Figure 4. Course of FEV1%pred after BOS onset in lung transplant recipi-
ents by type of transplant. Course for FEV1%pred after BOS onset for
single- (SLT) and bilateral lung transplant (BLT) recipients are shown,
adjusted for age, gender, time-to-BOS, pretransplant diagnosis, trans-
plant date, and 6-month pre-BOS relative change in FEV1 (rapid vs.
gradual onset of BOS). The steeper slope seen in BLT recipients during
the first 6 months was not significant when adjusted for differences in
FEV1%pred at BOS onset (p  0.17). Twenty-four months after BOS
onset, BLT recipients maintained a 42% higher FEV1%pred compared
with SLT recipients (p  0.0001). Numbers of SLT and BLT recipients
at the onset of each time interval are displayed at the bottom.
during Months 0–6 of BOS, p  0.19). However, 24 months after
BOS onset, patients with early onset had 16% lower FEV1%pred
compared with patients with late onset (p  0.01).
The estimated interaction of time to BOS onset and the
rapidity of onset displays the relative importance of rapid onset
compared with early onset in the future course of FEV1%pred.
Lowest to highest post-BOS FEV1%pred patterns over time
belonged to patients with early and rapid onset of BOS (Figure
6B), followed by patients with rapid onset and late BOS, gradual
onset and early BOS, and, finally, gradual onset and late BOS.
Patients with rapid and early onset of BOS had significantly
lower FEV1%pred at BOS onset (p  0.0001), steeper decline
in the first 6months (p 0.03), and lower FEV1%pred 24months
after onset of BOS (p  0.0001) as compared with the cohort
with gradual and late onset of BOS. Estimated interactions of rapid
BOS onset with gender and type of transplant showed a particularly
poor prognosis, as demonstrated by significantly lowerFEV1%pred
at 24 months after BOS onset for male patients (p  0.0002) and
BLT recipients (p 0.0005) with rapid BOS onset compared with
their gradual-onset counterparts (Figures 7A and 7B).
Effect of Histologic Diagnosis and Era of Transplantation on
the Course of FEV1 after BOS Onset
A total of 743 transbronchial biopsies performed between trans-
plantation and BOS onset were examined for acute rejection
and lymphocytic bronchitis in the study cohort. The histologic
Figure 5. Course of FEV1%pred after BOS onset in lung transplant recipi-
ents by pre-BOS FEV1 change (rapidity of BOS onset). FEV1 values at
the BOS onset date and FEV1 values collected approximately 6 months
earlier were used to calculate percent change in the 6 months before
BOS onset. Patients with 20% or greater change in the 6 months before
BOS onset were defined as having a rapid course of BOS onset; the
remaining patients were defined as experiencing a gradual onset. Both
FEV1%pred trajectories are adjusted for age, gender, pretransplant diag-
nosis, time-to-BOS, transplant date, and type of transplant. Patients
with rapid onset had an 18% lower FEV1%pred at onset compared with
gradual-onset patients (p0.0001). These patients continued to exhibit
a steeper decline in FEV1%pred during the first 6 months of BOS after
adjusting for gender, age, type of transplant, pretransplant diagnosis,
time-to-BOS, transplant date, and baseline FEV1%pred at BOS onset
(p  0.03). FEV1%pred at 24 months after BOS onset was higher in
the patients with gradual versus rapid onset (p  0.0002). Numbers
of patients with gradual-onset and rapid-onset BOS at the onset of each
time interval are displayed at the bottom.
diagnosis of lymphocytic bronchitis before BOS onset had no
significant effect on FEV1%pred at or after onset of BOS (data
not shown). The presence, number of episodes, or grade of acute
rejection also gave nonsignificant results in terms of predicting
FEV1%pred after BOS onset (data not shown).
To determine if calendar year had an influence on the course
of FEV1 after onset of BOS, transplant date was studied as
a variable. Later transplant years were associated with lower
FEV1%pred at BOS onset (p 0.03), with each additional trans-
plant year corresponding to an approximate decrease of 1% in
FEV1%pred at time of BOS. The course of FEV1%pred after
BOS onset (0–6 mo and 6–24 mo trajectories) was not signifi-
cantly different by transplant date (p  0.227 and p  0.240,
respectively). Similarly, the era of BOS onset (studied either as
a continuous or a categorical variable) was found to have no
significant effect on FEV1%pred at or after onset of BOS.
DISCUSSION
BOS is an important and frequent clinical entity in lung
transplant recipients that poses a challenge for physicians,
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Figure 6. (A ) Course of FEV1%pred after
BOS onset in lung transplant recipients
by time-to-BOS. Time of BOS onset was
defined as “early” if the onset of BOS oc-
curred within 2 years of transplantation;
otherwise it is termed “late.” Both FEV1%-
pred trajectories are adjusted for age,
gender, pretransplant diagnosis, type of
transplant, transplant date, and 6-month
pre-BOS relative change in FEV1 (rapid vs.
gradual onset of BOS). At 24months after
BOS onset, patientswith early onset had a
lower FEV1%pred comparedwith patients
with late onset (p  0.01). (B ) The esti-
mated interaction of time-to-BOS onset
and the rapidity of onset (rapid vs. grad-
ual). All trajectories are adjusted for other
significant variables, including age, gen-
der, pretransplant diagnosis, transplant
date, and type of transplant. Lowest to
highest post-BOS FEV1%pred patterns
over time belonged to patients with early
and rapid onset of BOS, followed by pa-
tients with rapid onset and late BOS,
gradual onset and early BOS, and, finally,
gradual onset and late BOS. Numbers of
patients with late and early BOS, and
those with gradual-onset (late and early)
and rapid-onset (late and early) BOS at
the onset of each time interval are dis-
played at the bottom.
researchers, and patients. Patients with BOS are identified at
various stages with different patient histories, and hence exhibit
varying values of FEV1%pred at onset and beyond (9). Although
predictors of time-to-BOS and estimates of survival in BOS
patients have been studied extensively, very few studies have
addressed the impact of various clinical variables on the course
of FEV1%pred after BOS onset.
In this study, we examined the course of FEV1 after BOS
onset in a large cohort of lung transplant recipients and the
effect of various clinical variables on its natural history. We
demonstrated that (1) FEV1%pred varies over time after BOS
onset with the steepest decline typically seen in the first 6months;
(2) BLT recipients have significantly higher FEV1%pred at BOS
diagnosis and continue to maintain that benefit for at least
2 years after onset of BOS; (3) female gender and pretransplant
IPF diagnosis are associated with steeper decline in FEV1%pred
in the first 6 months after BOS diagnosis; and (4) rapid BOS onset
( 20% decline in FEV1 6 mo before onset of BOS) is a strong
predictor of worse course of disease and is associated with lower
FEV1%pred at onset, steeper decline in FEV1%pred during the
first 6 months of BOS, and significantly lower FEV1%pred at
24 months after BOS onset.
This study is the first to investigate the multivariate relation-
ship between predictors known at BOS diagnosis and the course
of subsequent FEV1%pred in a large cohort of patients. Clinical
risk factors, such as type of transplantation, gender, and pretrans-
plant diagnosis, have been demonstrated to influence various
post–lung transplantation outcomes, such as survival, time-to-
onset of BOS, and functional status (14–17). However, the im-
pact of these important variables on course of FEV1 after BOS
onset had not been previously described. Heng and colleagues
studied progression of BOS in a cohort of patients who were in
stage 1 at diagnosis (8). Progression was defined as advancement
to stages 2 or 3, or death. Era of transplantation and number
of episodes of acute rejection were found to be significant pre-
dictors of progression. In the present study, the impact of year
of transplantation and histologic diagnosis of acute rejection, as
well as lymphocytic bronchitis, was studied on the linear course
of FEV1 after BOS onset. Furthermore, factors such as rapidity
(18) and time (19) of onset of BOS, which have been previously
associated with increased mortality after BOS onset, were stud-
ied for their impact on course of FEV1 after onset of BOS in a
multivariate model adjusting for other confounding variables.
The use of splines with the ability to change every 6 months
gave us a unique ability to assess, for the first time, the impact
of these variables on the course of FEV1 over time.
A clinically relevant finding of this study is that the course
of FEV1%pred for BOS patients is significantly improved in
BLT versus SLT recipients. A majority of the reports studying
the impact of transplant type have focused on survival as an
outcome. Hadjiliadis and colleagues reported increased risk of
BOS among SLT recipients (14). Earlier BOS onset and de-
creased survival after diagnosis of BOS was also seen in SLT
recipients with COPD (20). However, the association between
type of transplant and course of FEV1%pred after BOS onset has
not been studied. We demonstrate that, at 24 months after BOS
onset, BLT recipients continued to have 42% higher FEV1%pred
compared with SLT patients. This higher FEV1%pred could
potentially translate to a quality of life benefit, and is also consis-
tent with the longer survival of BLT recipients after BOS onset
reported previously (20). Our work also confirms previous work
done by Hadjiliadis and colleagues (20) noting a trend toward
longer BOS onset time in patients with BLT versus SLT. Impor-
tantly, the difference in course of FEV1 after BOS onset was
especially strong in patients with COPD. The small number of
IPF cases with BLT makes it difficult to reach firm conclusions
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Figure 7. Estimated interaction of rapid-
ity of BOS onset (rapid vs. gradual) with
gender (males vs. females) and type of
transplantation (bilateral lung transplant
[BLT] vs. single-lung transplant [SLT]).
Trajectories for these interactions are ad-
justed for the remaining significant vari-
ables including age, pretransplant diag-
nosis, time-to-BOS onset, transplant date,
and type of transplant (A ) or gender (B).
Particularly poor prognosis for male pa-
tients and BLT recipients with rapid BOS
onset compared with their gradual-onset
counterparts is noted. Numbers of male
and female patients with gradual and
rapid BOS, and those with gradual-onset
(BLT and SLT) and rapid-onset (BLT and
SLT) BOS at the onset of each time interval
are displayed at the bottom.
about this group. Because of small numbers of BLT recipients
in our cohort, further studies validating this finding and establish-
ing the impact of BLT versus SLT on quality of life and survival
after BOS onset are warranted.
An additional important finding of our study is the effect of
gender on the natural history of BOS. The issue of gender and
its implications on graft function have not been completely evalu-
ated in lung transplant recipients. In the analysis of post–lung
transplant survival, female gender was found to be associated
with increased mortality (21). Gender-related differences have
been reported in studies of quality of life in lung transplant
recipients (15). Female gender has been associated with signifi-
cantly lower 6-min walk distance values after lung transplanta-
tion (16). However, the impact of gender on the natural history
of FEV1 after BOS onset is not known. As such, we document
that female recipients experienced a significantly steeper decline
in FEV1%pred in the first 6 months after BOS onset compared
with their male counterparts and had lower FEV1%pred 2 years
after BOS diagnosis. Although the exact mechanism for these
differences is not known, several factors may contribute. Studies
in other solid organ transplantations point to a difference in
allograft rejection after transplantation in humans, with females
demonstrating a higher incidence of acute rejection (22, 23).
Female rat recipients of rat cardiac or skin allografts have shorter
graft survival compared with males (24–26), believed to be sec-
ondary to alteration of immunologic responses by the female
sex hormone, estrogen (24, 26). These data extend available
data supporting clinically relevant gender differences to lung
transplantation.
Another important, practical observation reflects the finding
that patients with IPF demonstrated significantly more rapid
decline in FEV1 compared with recipients with COPD after BOS
diagnosis. This expands on the findings in a previously studied,
small cohort of recipients with COPD (n  10) and IPF (n 
6)withBOS (17). These investigators suggested a survival benefit
in SLT recipients with a pretransplant diagnosis of COPD. Na-
tive lung physiology impacts pulmonary functions measured
after SLT. We have previously shown that early change in FEV1
[BOS (potential-BOS stage CBOS O-P)] in patients with under-
lying restrictive physiology has a higher predictive ability for
further progression to BOS than in patients with underlying
obstructive physiology (4). Similarly, differences in native lung
physiology (restrictive vs. obstructive) can potentially alter the
course of FEV1 after BOS onset in SLT recipients. Furthermore,
progressive airflow obstruction in patients with SLTs with ob-
structive lung disease might not always indicate the presence of
BOS, as factors such as native lung hyperinflation will also pres-
ent with worsening obstructive defect (5). It can be postulated
that new onset of obstruction with decline in FEV1 in a patient
with initial underlying restriction better identifies the true cohort
of patients with bronchiolitis obliterans, and hence the significant
decline seen in this group. Further confirmation of this finding
in an even larger multicentric cohort of IPF cases is suggested.
Our study identifies rapid BOS onset as a very important
predictor of poorer subsequent FEV1%pred. In particular, a fall
in FEV1 greater than 20% in the 6 months preceding BOS onset
is associated with (1) lower FEV1%pred at the time of BOS
diagnosis, (2) steeper decline in the first 6 months after onset,
and (3) lower FEV1%pred 2 years after onset when compared
with those with a more gradual onset. The impact of rapidity of
onset of BOS on survival has been demonstrated, with poorer
prognosis seen in patients with acute onset of BOS; however,
the course of FEV1 after onset of BOS in these groups was not
reported (18). The authors classified patients as having rapid
(acute) versus gradual (chronic) BOS based on knowing FEV1
values from BOS onset to the end of follow-up, which is of
limited use to the clinician attempting to classify patients when
they initially present with BOS. In our study, we define rapid
and gradual onset based on FEV1 information available in the
6-month period preceding BOS diagnosis. For example, if a
1198 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 175 2007
patient with a BOS FEV1 value of 2.5 L had an FEV1 value of
3.2 L 6months earlier, it was determined that this patient decreased
20% or more during this period (i.e., decrease was [(3.2  2.5 L)/
3.2 L]  100  22%). This simple variable can be easily deter-
mined at bedside, and provides valuable information regarding
the further course of pulmonary function.
The effect of BOS onset time on prognosis after onset has
also been studied with varying conclusions. In one study, this
variable was not found to be a significant predictor of disease
progression, defined as advancement of BOS stage 1 to stages 2
or 3, or death (8). However, another group demonstrated differ-
ences in FEV1 course after BOS onset in 29 SLT recipients (19).
In our cohort, a trend toward a greater decline in FEV1%pred
was observed in patients with early BOS onset. Our findings
were consistent with those of Brugiere and colleagues in that
lung transplant recipients with early onset of BOS had signifi-
cantly lower FEV1%pred (17%) at 24 months after onset of BOS
as compared with those with late onset of disease (19). Further
study of acuteness of onset (rapid vs. gradual) and time-to-onset
(early vs. late) demonstrates lowest trajectories of FEV1%pred in
the cohort with early, rapid BOS onset.
This study provides important insight into the longitudinal
behavior of FEV1%pred in a large cohort of lung transplant
recipients; these results have potential implications for patient
care, pretransplant lung allocation, and the design of therapeutic
trials aimed at amelioratingBOS-associated loss of lung function.
These findings include documentation of a greater decline within
the first 6 months after BOS diagnosis, gender-specific differ-
ences in the rate of progression, procedure- and pretransplant
diagnosis–related differences (SLT vs. BLT and IPF vs. COPD),
and additional predictors of an accelerated post-BOS decline
(steeper pre-BOS decline or rapid onset, and early onset of
BOS). Investigators on BOS clinical studies should strongly con-
sider stratification of patients by factors that are most likely to
influence post-BOS FEV1 behavior so as to minimize confound-
ers in interpretation of therapeutic response. Similarly, the fac-
tors that predict future FEV1%pred behavior should be consid-
ered in assessing each newly diagnosed BOS patient’s prognosis
and therapeutic options.
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